Phaseline

Companies › Kinaset Therapeutics

Kinaset Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Frevecitinib (KN-002)
FGFR2 inhibitor
FGFR2Phase 2Severe AsthmaNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07532265Frevecitinib (KN-002)Phase 2Severe AsthmaRespiratoryNov 2027

Targets

FGFR2 (1)

Companies with the same targets

Tyra Biosciences KinoTeck Therapeutics AstraZeneca Johnson & Johnson (Janssen) Hangzhou Zhongmei Huadong Pharmaceutical Taiho Oncology Elevar Therapeutics BeOne Medicines Exelixis QED Therapeutics, a BridgeBio company

Companies built like this

Expedition Therapeutics Dragonboat Biopharmaceutical Company Melius Pharma Jianmin Pharmaceutical Group Endeavor Biomedicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.